ReviewCancers2022

Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors.

Frank Rojas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.